Search clinical trials for: danoprevir ritonavir

Total 892 results

Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

HCV

China
Huoshenshan Hospital
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection

COVID-19

China
Hoffmann-La Roche

Completed

A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy Controls

Healthy Volunteer

Poland, Hungary
Hoffmann-La Roche

Completed

A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment

Healthy Volunteer

Slovakia, United States, Czech Republic
Hoffmann-La Roche

Completed

A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy Volunteers

Healthy Volunteer

United States
Merck Sharp & Dohme LLC

Completed

A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005)

Hepatitis C
Hoffmann-La Roche

Completed

A Relative Bioavailability Study of Danoprevir and Ritonavir in Healthy Volunteers

Healthy Volunteer

New Zealand
Hoffmann-La Roche

Completed

A Study of The Relative Bioavailability of Ritonavir-Boosted Danoprevir Fixed Dose Combination Tablets in Healthy Volunteers

Healthy Volunteer

New Zealand
Hoffmann-La Roche

Completed

A Study of Danoprevir in Combination With Low-Dose Ritonavir in Healthy Subjects

Healthy Volunteer

France
Hoffmann-La Roche

Completed

A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers

Healthy Volunteer

United States
Merck Sharp & Dohme LLC

Terminated

Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029)

Chronic Hepatitis C Infection
Hoffmann-La Roche

Completed

A Pharmacokinetic And Bioavailability Study of Intravenous Danoprevir in Healthy Volunteers

Healthy Volunteer

Netherlands
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

New Zealand, Poland, France
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

Hepatitis C, Chronic

United States, Canada, Slovakia, Poland, New Zealand, France, Australia
Hoffmann-La Roche

Withdrawn

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment

Hepatitis C, Chronic
Hoffmann-La Roche

Completed

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

Hepatitis C, Chronic

France, Germany, United States, New Zealand
Hoffmann-La Roche

Completed

A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients

Hepatitis C, Chronic

New Zealand, Australia
Hoffmann-La Roche

Completed

A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

United States, Spain, France, Canada, Germany, Austria, Australia, Brazil, United Kingdom, Italy, Mexico, Poland, Puerto Rico
Hoffmann-La Roche

Completed

A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers

Healthy Volunteer

United States
Ascletis Pharmaceuticals Co., Ltd.

Completed

Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China

Healthy
Hoffmann-La Roche

Completed

A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir

Healthy Volunteer

United States
Ascletis Pharmaceuticals Co., Ltd.

Completed

Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

HCV

China
Hoffmann-La Roche

Completed

A Study of RO5190591 (Danoprevir) in Healthy Volunteers

Healthy Volunteer

United States
Merck Sharp & Dohme LLC

Withdrawn

Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)

Chronic Genotype 1 Hepatitis C Virus Infection
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan

Chronic Hepatitis C
Ascletis Pharmaceuticals Co., Ltd.

Completed

Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China

Healthy
Hoffmann-La Roche

Completed

A Study to Evaluate the Effect of Danoprevir/Ritonavir on the Pharmacokinetics of Escitalopram and S-Demethylcitalopram in Healthy Volunteers

Healthy Volunteer

United States
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis

Hepatitis C, Chronic

Taiwan, Korea, Republic of, Thailand
Hoffmann-La Roche

Completed

A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers

Healthy Volunteer

United States
Hoffmann-La Roche

Completed

A Study on the Interaction Between Danoprevir/Ritonavir and Methadone

Healthy Volunteer

United States
Hoffmann-La Roche

Completed

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection

Hepatitis C, Chronic

France, Germany, United States, Spain, Canada, Austria, United Kingdom, Puerto Rico, Italy, Brazil, Mexico
Hoffmann-La Roche

Completed

A Study to Evaluate The Effects of Two Different Meal Types, Omeprazole And Ranitidine On Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Volunteers

Healthy Volunteer

United States
Hoffmann-La Roche

Completed

A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

Hepatitis C, Chronic

United States, Canada, Australia, France, Germany, Austria, Italy
University of Extremadura

Active, not recruiting

Influence of Co-diagnosis of Chronic Fatigue Syndrome in Patients With Fibromyalgia.

Fibromyalgia | Chronic Fatigue Syndrome | Comorbidities and Coexisting Conditions

Spain
Merck Sharp & Dohme LLC

Completed

Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)

Hepatitis C, Chronic
Pfizer

Completed

Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.

Biological Availability

Belgium
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

Chronic Hepatitis C
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)

Hepatitis C, Chronic
Pfizer

Not yet recruiting

A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants

Healthy Participants | Biological Availability
Jiangsu Simcere Pharmaceutical Co., Ltd.

Completed

To Evaluate SSD8432/ Ritonavir in Adults With COVID-19

COVID-19 Patients

China
Karolinska Institutet
Karolinska University Hospital; Pfizer

Recruiting

imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC)

COVID-19 | Post-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | POTS - Postural Orthostatic Tachycardia Syndrome | Postinfectious Inflammation | Postinfectious Disorder

Sweden
Drugs for Neglected Diseases
University of Cape Town; Medecins Sans Frontieres, Netherlands; UBS Optimus Foundation and other collaborators

Completed

Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB

Acquired Immunodeficiency Syndrome | Tuberculosis

South Africa
Jiangsu Simcere Pharmaceutical Co., Ltd.

Recruiting

A Phase I Clinical Study of SSD8432 in Healthy Adult Subjects

Healthy Participants

China
Fujian Akeylink Biotechnology Co., Ltd.

Active, not recruiting

Food Effects of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants

COVID-19 Respiratory Infection

China
Qilu Pharmaceutical Co., Ltd.

Recruiting

A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants

COVID-19

China
The HIV Netherlands Australia Thailand Research...
Ministry of Education, Thailand

Completed

Efficacy and Safety of Single Versus Double Ritonavir-boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens

HIV Infections | HIV Infection

Thailand
Pfizer

Completed

A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women

Healthy Participants

Belgium
Pfizer

Completed

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants

Healthy Participants | Biological Availability

United States
GlaxoSmithKline

Terminated

Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects

HIV-1

Australia, Belgium, Canada, France, Germany, Greece, Italy, Spain, United Kingdom

3

Subscribe